Yahoo
OTC Markets OTCPK - Delayed Quote USD

Ion Beam Applications SA (IOBCF)

18.28 0.00 (0.00%)
At close: October 30 at 4:00:00 PM EDT

Key Executives

Amounts are as of December 31, 2025 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
Name Title Pay Exercised Year Born
Mr. Olivier Legrain
CEO, MD & Vice Chairman 1.1M -- 1968
Mr. Yves Jongen
Founder, Chief Research Officer & Executive Director 880.01k -- 1947
Ms. Catherine Vandenborre
CFO, Chief Ventures & Corporate Officer 277.17k -- 1971
Mr. Henri de Romree
Deputy CEO, Internal Director & Managing Director 652.37k -- 1976
Mr. Thomas Pevenage
Head of Corporate Finance & Investments -- -- --
Olivier Lechien
Corporate Communication Director -- -- --
Thomas Canon
Sustainability Program Director -- -- --
Bruno Scutnaire
President of IBA RadioPharma Solutions -- -- --

Ion Beam Applications SA

3, Chemin du Cyclotron
Louvain-la-Neuve, 1348
Belgium
32 1 047 58 11 https://www.iba-worldwide.com
Sector: 
Healthcare
Industry: 
Medical Devices
Full Time Employees: 
2,264

Description

Ion Beam Applications SA designs, produces, and markets solutions for cancer diagnosis and treatments, serious illnesses, and industrial applications in Belgium, the United States, China, Germany, and India. It operates through four segments, Clinical Proton Therapy; Clinical Dosimetry; IBA Technologies; and IBA Corporate. The company develops ConformalFLASH, a novel technique using the proton Bragg peak; DynamicARC, a technique that allows dynamic spot scanning irradiation and energy switching while the gantry is rotating; Proteus ONE, a compact proton therapy system transforming cancer treatment; Proteus PLUS, a proton therapy solution for cancer centers; and dosimetry solutions that includes radiation therapy; medical imaging; and QUASAR that offers a portfolio of sophisticated phantoms supporting MR guided radiation therapy, motion management, surface guided radiation therapy, geometric distortion analysis, and machine targeting solutions. It also offers radio pharma solutions, including radioisotopes, cyclotrons, and radiochemistry, as well as other integrated and industrial solutions, and services. In addition, the company is involved in construction of proton therapy, and other accelerators equipment and installation services; and operation and maintenance services, as well as sales a license for intellectual property. The company has strategic research and development partnership with SCK CEN, a Belgian nuclear research center focusing on the development of Actinium-225, a radioactive isotope for the treatment of cancer. Ion Beam Applications SA was incorporated in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

Corporate Governance

Ion Beam Applications SA’s ISS Governance QualityScore as of October 1, 2026 is 10. The pillar scores are Audit: 9; Board: 9; Shareholder Rights: 10; Compensation: 9.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Upcoming Events

August 27, 2026 at 8:00 PM UTC

Ion Beam Applications SA Earnings Date

Recent Events

June 15, 2026 at 12:00 AM UTC

Ex-Dividend Date

Related Tickers

Mobilize your Website
View Site in Mobile | Classic
Share by: